November 21, 2020 Stock Watch – ImmuPharma (Daily Mail | 21 November 2020) Read More November 20, 2020 ImmuPharma’s US partner to meet with FDA in December regarding Lupuzor trial Read More November 20, 2020 ImmuPharma says US partner makes regulatory and operational progress ahead of phase III trial of lupus drug Read More September 02, 2020 ImmuPharma raises £6.5m to invest in pipeline of up-and-coming drug Read More July 27, 2020 ImmuPharma notes new FDA submission for Lupuzor™ Read More July 27, 2020 Rachel Brazil, Chemisty World, talks to the people trying to create foldamers including Dimitri Dimitriou, chief executive, Immupharma PLC Read More July 27, 2020 ImmuPharma partner looks to streamline phase III approval process for lupus drug Read More June 11, 2020 ImmuPharma attracts first funding from US healthcare specialists – 11 June 2020 Read More May 14, 2020 ImmuPharma surges as US study shows potential for Lupuzor to reduce coronavirus symptoms – 14 May 2020 Read More February 06, 2020 ImmuPharma expects second phase III lupus trial to get underway as soon as possible this year Read More December 19, 2019 ImmuPharma commences trading on Euronext Growth Brussels 19 December 2019 Read More December 13, 2019 ImmuPharma PLC (LON:IMM) announced that its shares will be dual-listed on Euronext Growth Brussels with effect from 19 December 2019, following approval by the European exchange, a move which will bring the company “additional visibility among European investor Read More 1234
November 20, 2020 ImmuPharma’s US partner to meet with FDA in December regarding Lupuzor trial Read More
November 20, 2020 ImmuPharma says US partner makes regulatory and operational progress ahead of phase III trial of lupus drug Read More
July 27, 2020 Rachel Brazil, Chemisty World, talks to the people trying to create foldamers including Dimitri Dimitriou, chief executive, Immupharma PLC Read More
July 27, 2020 ImmuPharma partner looks to streamline phase III approval process for lupus drug Read More
June 11, 2020 ImmuPharma attracts first funding from US healthcare specialists – 11 June 2020 Read More
May 14, 2020 ImmuPharma surges as US study shows potential for Lupuzor to reduce coronavirus symptoms – 14 May 2020 Read More
February 06, 2020 ImmuPharma expects second phase III lupus trial to get underway as soon as possible this year Read More
December 19, 2019 ImmuPharma commences trading on Euronext Growth Brussels 19 December 2019 Read More
December 13, 2019 ImmuPharma PLC (LON:IMM) announced that its shares will be dual-listed on Euronext Growth Brussels with effect from 19 December 2019, following approval by the European exchange, a move which will bring the company “additional visibility among European investor Read More
